ATAI
Price:
$4.4
Market Cap:
$829.95M
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Industry
Medical - Pharmaceuticals
IPO Date
2021-06-18
Stock Exchange
NASDAQ
Ticker
ATAI
According to Atai Beckley N.V’s latest financial reports and current stock price. The company's current PE Ratio is -5.30. This represents a change of 73.38% compared to the average of -3.06 of the last 4 quarters.
The mean historical PE Ratio of Atai Beckley N.V over the last ten years is -37.09. The current -5.30 PE Ratio has changed 1.33% with respect to the historical average. Over the past ten years (40 quarters), ATAI's PE Ratio was at its highest in in the March 2021 quarter at 1.10K. The PE Ratio was at its lowest in in the June 2020 quarter at -46.38.
Average
-37.09
Median
-7.41
Minimum
-173.64
Maximum
-1.43
Discovering the peaks and valleys of Atai Beckley N.V PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 90.08%
Maximum Annual PE Ratio = -1.43
Minimum Annual Increase = -82.89%
Minimum Annual PE Ratio = -173.64
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.43 | -74.37% |
| 2023 | -5.57 | 90.08% |
| 2022 | -2.93 | -68.32% |
| 2021 | -9.24 | -68.89% |
| 2020 | -29.72 | -82.89% |
The current PE Ratio of Atai Beckley N.V (ATAI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.31
5-year avg
-9.78
10-year avg
-37.09
Atai Beckley N.V’s PE Ratio is greater than Nektar Therapeutics (-9.05), greater than Inhibrx Biosciences, Inc. (-8.72), greater than Enliven Therapeutics, Inc. (-11.13), greater than Dianthus Therapeutics, Inc. (-13.37), greater than ORIC Pharmaceuticals, Inc. (-8.33), greater than Syndax Pharmaceuticals, Inc. (-5.49), less than Relay Therapeutics, Inc. (-4.63), greater than Amylyx Pharmaceuticals, Inc. (-9.06), greater than Immatics N.V. (-10.68), less than Sana Biotechnology, Inc. (-4.90),
| Company | PE Ratio | Market cap |
|---|---|---|
| -9.05 | $1.17B | |
| -8.72 | $1.27B | |
| -11.13 | $1.27B | |
| -13.37 | $1.62B | |
| -8.33 | $1.11B | |
| -5.49 | $1.71B | |
| -4.63 | $1.39B | |
| -9.06 | $1.20B | |
| -10.68 | $1.44B | |
| -4.90 | $1.38B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atai Beckley N.V using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Atai Beckley N.V or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Atai Beckley N.V's PE Ratio?
How is the PE Ratio calculated for Atai Beckley N.V (ATAI)?
What is the highest PE Ratio for Atai Beckley N.V (ATAI)?
What is the 3-year average PE Ratio for Atai Beckley N.V (ATAI)?
What is the 5-year average PE Ratio for Atai Beckley N.V (ATAI)?
How does the current PE Ratio for Atai Beckley N.V (ATAI) compare to its historical average?